NEUROGENE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.23 USD | -0.98% |
|
+15.95% | +92.11% |
| 06-03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
| 06-03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NEUROGENE INC. | Other Biotechnology & Medical Research | -0.98% | +15.95% | +92.11% | - | - | 483M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- NGNE Stock
- Charts Neurogene Inc.
- Comparison Chart
